Vivani Medical, Inc. (NASDAQ:VANI) announced that the U.S. FDA has cleared its Investigational New Drug Application for NPM-119, paving the way for the commencement of the LIBERATE-1 Phase 1 trial.
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset ...
A Cochrane Systematic Review that set out to assess the effectiveness and tolerability of subdermal implantable contraceptives compared to other reversible methods of contraception found that they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback